Lupin and Mylan Launch Nepexto (biosimilar, etanercept) in Germany

 Lupin and Mylan Launch Nepexto (biosimilar, etanercept) in Germany

Lupin and Mylan Launch Nepexto (biosimilar, etanercept) in Germany

Shots:

  • The companies launch Nepexto, a biosimilar referencing Amgen’s Enbrel, and is indicated for the mod. to sev. RA, JIA from the age of 2yrs., active and progressive PsA, severe axSpA, mod. to sev. PsO and chronic severe PsO in children and adolescents from the age of 6yrs.
  • Nepexto is available as a solution for injection in a pre-filled pen and prefilled syringe and has shown equivalent efficacy and safety to Enbrel
  • The EC has approved MAA to Nepexto on Jun 04, 2020, following CHMP’s positive opinion. The approval underlines the scientific success of Mylan’s biologics program and expands Mylan’s therapeutic portfolio for immune-mediated diseases including RA

Click here ­to­ read full press release/ article | Ref: Lupin | Image: mAbxience

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post